knowledge -WSS

knowledge

author：knowledge 2025-10-04 03:46:53 - browse：67

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Close Medicare's dangerous gaps in addiction treatment coverage

Wikipedia

hotspot

WSS

STAT readers on older presidents, polypills, Medicare, and more

Medicare inequities exacerbate Puerto Rico’s health disparities

Medicare inequities exacerbate Puerto Rico’s health disparities

Orangutan used medicinal plant to treat wound, first time ever seen

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Q&A: Jennifer Adair on making gene therapy available globally

hotspot

knowledge

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Moonlake's readout produced a cash windfall. Risks remain

Q&A: Jennifer Adair on making gene therapy available globally

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Bright Health sells Medicare Advantage business to Molina

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Hollywood unions extend contract negotiations for actors

R1 RCM gets $5.8 billion buyout offer from private equity firm

entertainment

Why palliative psychiatry is worth discussing

NIH study of ME/CFS points to clear biological hallmarks

Cue Health's Covid

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Cue Health's Covid

With competition flaring, obesity drug hits goal in liver disease study

explore

Wikipedia

hotspot

hotspot